Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eplerenone in NYHA Class II Chronic Systolic Heart Failure
NCT00232180Phase 3Completed
- Sponsor
- Viatris
- Start
- Mar 2006
- Primary completion
- May 2010
- Modality
- Orthosteric Ligands
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial in systolic heart failure (HFrEF) comparing Eplerenone with Placebo (2 arms). Primary endpoint: First Occurrence of Cardiovascular Mortality or Hospitalization Due to Heart Failure at 50 months. Started Mar 2006; status: completed.
02
Drugs
eplerenone
03
Conditions
systolic heart failure (HFrEF)
Beyond the preview
Go deeper on NCT00232180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00232180.